Table 3.
Characteristics of radiotherapy and non-radiotherapy groups in the before and after PSM cohorts.
| Before PSM cohort (n=416) | After PSM cohort (n=250) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics | T(n=416) | NRT(n=266) | RT(n=150) | P | T(n=250) | NRT(n=125) | RT(n=125) | p | SMD |
| Age | 0.102 | 0.640 | 0.021 | ||||||
| Years (median[IQR]) | 416 | 77.0[68.0,84.0] | 74.5[66.0,83.0] | 250 | 75.0[66.0,82.0] | 75.0[65.0,83.0] | |||
| Race (%) | 0.645 | 0.415 | 0.168 | ||||||
| Black | 26 | 17(6.4) | 9 (6.0) | 19 | 11(8.8) | 8 (6.4) | |||
| White | 380 | 244(91.7) | 136 (90.7) | 224 | 112(89.6) | 112(89.6) | |||
| Others | 10 | 5(1.9) | 5 (3.3) | 7 | 2(1.6) | 5 (4.0) | |||
| Sex (%) | 0.450 | 1.000 | 0.020 | ||||||
| Male | 320 | 201(75.6) | 119 (79.3) | 201 | 101(80.8) | 100 (80.0) | |||
| Female | 96 | 65(24.4) | 31 (20.7) | 49 | 24(19.2) | 25 (20.0) | |||
| T stage (%) | 0.680 | 0.592 | 0.213 | ||||||
| Tis | 3 | 1 (0.4) | 2 (1.3) | 1 | 0 (0.0) | 1 (0.8) | |||
| T1 | 85 | 54 (20.3) | 31 (20.7) | 47 | 21(16.8) | 26 (20.8) | |||
| T2 | 266 | 174 (65.4) | 92 (61.3) | 160 | 84 (67.2) | 76 (60.8) | |||
| T3 | 25 | 16(6.0) | 9 (6.0) | 16 | 9(7.2) | 7(5.6) | |||
| T4 | 37 | 21 (7.9) | 16 (10.7) | 26 | 11 (8.8) | 15(12.0) | |||
| N stage (%) | 0.313 | 1.000 | 0.019 | ||||||
| N0 | 334 | 218(82.0) | 116(77.3) | 193 | 96(76.8) | 97(77.6) | |||
| N1 | 82 | 48(18.0) | 34(22.7) | 57 | 29(23.2) | 28(22.4) | |||
| Bone metastases(%) | 1.000 | 0.701 | 0.073 | ||||||
| Yes | 42 | 27(10.2) | 15(10.0) | 31 | 17(13.6) | 14(11.2) | |||
| No | 374 | 239(89.8) | 135(90.0) | 219 | 108(86.4) | 111(88.8) | |||
| Liver metastases(%) | 0.061 | 0.075 | 0.250 | ||||||
| Yes | 61 | 46(17.3) | 15(10.0) | 37 | 24(19.2) | 13(10.4) | |||
| No | 355 | 220(82.7) | 135(90.0) | 213 | 101(80.8) | 112(89.6) | |||
| Lung metastases(%) | 0.133 | 0.497 | 0.129 | ||||||
| Yes | 18 | 15(5.6) | 3(2.0) | 9 | 6(4.8) | 3(2.4) | |||
| No | 398 | 251(94.4) | 147(98.0) | 241 | 119(95.2) | 122(97.6) | |||
| Brain metastases(%) | 0.268 | 0.245 | 0.222 | ||||||
| Yes | 4 | 1(0.4) | 3(2.0) | 3 | 0(0.0) | 3(2.4) | |||
| No | 412 | 265(99.6) | 147(98.0) | 247 | 125(100.0) | 122(97.6) | |||
| Tumor size | <0.001* | 1.000 | <0.001 | ||||||
| Centimetre (median[IQR]) | 416 | 11.0[5.0,11.0] | 5.0[3.0,11.0] | 250 | 6.0[4.0,11.0] | 6.0[4.0,11.0] | |||
| Chemotherapy | <0.001* | 1.000 | <0.001 | ||||||
| Yes | 255 | 134(50.4) | 121(80.7) | 196 | 98(78.4) | 98(78.4) | |||
| No | 161 | 132(49.6) | 29(19.3) | 54 | 27(21.6) | 27(21.6) | |||
PSM, propensity score matching; RT, radiotherapy; NRT, without radiotherapy; IQR, interquartile range; T stage, tumour stage; N stage, node stage; p, P value; SMD, STD Mean Difference.